Patent: 10,159,700
✉ Email this page to a colleague
Summary for Patent: 10,159,700
| Title: | Method of treating Clostridium difficile infection |
| Abstract: | A composition of Lactobacillus fermentum GMNL-296 and a use of Lactobacillus fermentum GMNL-296 for producing a composition to improve the infection symptoms of Clostridium difficile are provided. The Lactobacillus fermentum GMNL-296 is to promote the expression of anti-inflammatory cytokine IL-10 and Treg cell related transcription factors, so that the infection symptoms of weight loss and intestinal abnormalities are improved. |
| Inventor(s): | Yi-Hsing Chen, Wan-Hua Tsai |
| Assignee: | Genmont Biotech Inc |
| Application Number: | US15/366,193 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,159,700
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Auxilium Pharmaceuticals, Inc. | XIAFLEX | collagenase clostridium histolyticum | For Injection | 125338 | February 02, 2010 | ⤷ Start Trial | 2036-12-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,159,700
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| United States of America | 2018050072 | ⤷ Start Trial |
| Taiwan | I598103 | ⤷ Start Trial |
| Taiwan | 201808314 | ⤷ Start Trial |
| China | 107760615 | ⤷ Start Trial |
| Australia | 2017200236 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
